Literature DB >> 11594296

Hypoglycaemia and cognitive function in diabetes.

B M Frier1.   

Abstract

The human brain is almost totally dependent on a continuous supply of glucose, deprivation of which rapidly causes malfunction. In the brain there are regional differences in the susceptibility to neuroglycopenia with the cerebral cortex being most sensitive while deeper structures are more resistant. A fall in blood glucose provokes a hierarchy of responses including secretion of counter-regulatory hormones and development of warning symptoms which alert the individual to treat the hypoglycaemia. Symptoms are generated when blood glucose falls to specific threshold concentrations, although these are dynamic and can be modified by various factors. Symptoms can be classified as autonomic and neuroglycopenic, with the latter being related to altered cognitive functioning. Acute hypoglycaemia produces electroencephalographic (EEG) changes as well as neurophysiological abnormalities including increased latency and/or reduced amplitude of sensory evoked potentials. At blood glucose below 3 mmol/l cognitive functioning becomes impaired but the degree of dysfunction differs in various domains and a battery of psychometric tests are required to assess impairment of cognitive function during hypoglycaemia. Complex, attention-demanding and speed-dependent responses are most impaired with accuracy often preserved at the expense of speed. Cognitive function does not recover fully until 40-90 min after blood glucose is restored to normal. Hypoglycaemia also provokes changes in mood, increases anxiety and may induce depression and fear of further hypoglycaemia, which can modify behaviour and influence quality of glycaemic control. Recurrent severe hypoglycaemia may have long-term sequelae in the form of cumulative cognitive impairment and impaired awareness of hypoglycaemia.

Entities:  

Mesh:

Year:  2001        PMID: 11594296

Source DB:  PubMed          Journal:  Int J Clin Pract Suppl        ISSN: 1368-504X


  11 in total

Review 1.  Severe hypoglycemia in adults.

Authors:  Mary F Carroll; Mark R Burge; David S Schade
Journal:  Rev Endocr Metab Disord       Date:  2003-05       Impact factor: 6.514

Review 2.  Glycemic control and weight reduction without causing hypoglycemia: the case for continued safe aggressive care of patients with type 2 diabetes mellitus and avoidance of therapeutic inertia.

Authors:  Stanley S Schwartz; Benjamin A Kohl
Journal:  Mayo Clin Proc       Date:  2010-11-24       Impact factor: 7.616

Review 3.  Management of diabetes mellitus medications in the nursing home.

Authors:  Linda Haas
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

4.  Cognitive, neurophysiologic and metabolic sequelae of previous hypoglycemic coma revealed by hyperinsulinemic-hypoglycemic clamp in type 1 diabetic patients.

Authors:  Alberto Maran; Cristina Crepaldi; Franco Del Piccolo; Ian Macdonald; Lisa Zarantonello; Angelo Avogaro; Piero Amodio
Journal:  Metab Brain Dis       Date:  2017-06-06       Impact factor: 3.584

Review 5.  Metformin and cognition from the perspectives of sex, age, and disease.

Authors:  Kiran Chaudhari; Conner D Reynolds; Shao-Hua Yang
Journal:  Geroscience       Date:  2020-01-02       Impact factor: 7.713

6.  The impact of type 1 diabetes on neural activity serving attention.

Authors:  Christine M Embury; Alex I Wiesman; Timothy J McDermott; Amy L Proskovec; Elizabeth Heinrichs-Graham; Grace H Lord; Kaitlin L Brau; Andjela T Drincic; Cyrus V Desouza; Tony W Wilson
Journal:  Hum Brain Mapp       Date:  2018-10-27       Impact factor: 5.038

7.  Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes.

Authors:  Nandu Thalange; Larry Deeb; Violeta Iotova; Tomoyuki Kawamura; Georgeanna Klingensmith; Areti Philotheou; Janet Silverstein; Stefano Tumini; Ann-Marie Ocampo Francisco; Ona Kinduryte; Thomas Danne
Journal:  Pediatr Diabetes       Date:  2015-02-12       Impact factor: 4.866

8.  Cognitive dysfunction associated with anti-glutamic acid decarboxylase autoimmunity: a case-control study.

Authors:  Masahito Takagi; Yasushi Ishigaki; Kenji Uno; Shojiro Sawada; Junta Imai; Keizo Kaneko; Yutaka Hasegawa; Tetsuya Yamada; Ai Tokita; Kazumi Iseki; Shigenori Kanno; Yoshiyuki Nishio; Hideki Katagiri; Etsuro Mori
Journal:  BMC Neurol       Date:  2013-07-09       Impact factor: 2.474

9.  Insulin degludec is not associated with a delayed or diminished response to hypoglycaemia compared with insulin glargine in type 1 diabetes: a double-blind randomised crossover study.

Authors:  Gerd Koehler; Simon Heller; Stefan Korsatko; Carsten Roepstorff; Søren Rasmussen; Hanne Haahr; Thomas R Pieber
Journal:  Diabetologia       Date:  2013-09-22       Impact factor: 10.122

10.  Fear of hypoglycaemia: defining a minimum clinically important difference in patients with type 2 diabetes.

Authors:  Tom Stargardt; Linda Gonder-Frederick; Karl J Krobot; Charles M Alexander
Journal:  Health Qual Life Outcomes       Date:  2009-10-22       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.